Program
vonsetamig
Also written as “Vonsetamig” and “REGN5459”.
Its studies are mostly in Lupus Nephritis · Renal Insufficiency, Chronic · Multiple Myeloma, led by Regeneron Pharmaceuticals.
Furthest: phase 2, since Aug 29, 20193 company-led studies, 2 open or runningNext primary completion: Nov 22, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Regeneron Pharmaceuticals | 32 open or running | phase 2since Aug 29, 2019 | Aug 29, 2019 | Nov 22, 2027phase 2 · NCT05092347 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 29, 2019First study: phase 2 study in Multiple MyelomaFirst studyNCT04083534 · 43 enrolled · United States
- Oct 22, 2021Phase 2 study in Renal Insufficiency, ChronicNCT05092347 · 43 enrolled · United States
- May 8, 2025Phase 1 study in Lupus NephritisNCT06975787 · 90 planned · United States, France, Germany and more
Ahead
- Nov 22, 2027Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT05092347
- Sep 10, 2029Primary completion: phase 1 study in Lupus NephritisNCT06975787
TargetBeta
“A human bispecific antibody directed against the tumor-associated antigen (TAA) human B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and another directed against the T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elranatamabrule | Pfizer | phase 4 | 15 |
| linvoseltamabrule | Regeneron Pharmaceuticals | phase 4 | 13 |
| teclistamabrule | Johnson & Johnson | phase 4 | 11 |
| etentamig | AbbVie | phase 3 | 11 |
| ramantamig | Johnson & Johnson | phase 3 | 7 |
| Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 | Sino Biopharmaceutical | phase 3 | 4 |
| GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003rule | Innovent Biologics | phase 3 | 4 |
| cizutamigrule | UCB | phase 2 | 5 |
| Anti-BCMA/CD38/CD3 Trispecific Antibody ABBV-2001 | AbbVie | phase 2 | 2 |
| LVV Expressing VSV Glycoprotein/Anti-CD3 scFv Containing Transgene Encoding for Anti-BCMA CAR KLN-1010rule | kelonia-therapeutics-inc | phase 1 | 1 |
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06975787Lupus Nephritis · United States, France, Germany and more | 1 | Recruiting | Sep 10, 2029 | 90 |
| NCT05092347Renal Insufficiency, Chronic · United States | 2 | Active, not recruiting | Nov 22, 2027 | 43 |
| NCT04083534Multiple Myeloma · United States | 2 | Completed | May 1, 2025 | 43 |
How it is read
Names in the registry
- “Vonsetamig”, 2 entries
- “REGN5459”, 1 entry
Conditions, from the studies’ own filings
- Lupus Nephritis, 1 study
- Renal Insufficiency, Chronic, 1 study
- Multiple Myeloma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.